Ethosuximide: From Bench to Bedside
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Ethosuximide, 2‐ethyl‐2‐methylsuccinimide, has been used extensively for “petit mal” seizures and it is a valuable agent in studies of absence epilepsy. In the treatment of epilepsy, ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy. Commonly observed side effects of ethosuximide are dose dependent and involve the gastrointestinal tract and central nervous system. Ethosuximide has been associated with a wide variety of idiosyncratic reactions and with hematopoietic adverse effects. Typical absence seizures are generated as a result of complex interactions between the thalamus and the cerebral cortex. This thalamocortical circuitry is under the control of several specific inhibitory and excitatory systems arising from the forebrain and brainstem. Corticothalamic rhythms are believed to be involved in the generation of spike‐and‐wave discharges that are the characteristic electroencephalographic signs of absence seizures. The spontaneous pacemaker oscillatory activity of thalamocortical circuitry involves low threshold T‐type Ca 2+currents in the thalamus, and ethosuximide is presumed to reduce these low threshold T‐type Ca 2+currents in thalamic neurons. Ethosuximide also decreases the persistent Na+and Ca 2+‐activated K+currents in thalamic and layer V cortical pyramidal neurons. In addition, there is evidence that in a genetic absence epilepsy rat model ethosuximide reduces cortical γ‐aminobutyric acid (GABA) levels. Also, elevated glutamate levels in the primary motor cortex of rats with absence epilepsy (but not in normal animals) are reduced by ethosuximide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1989) · Epilepsia · doi:10.1111/j.1528-1157.1989.tb05316.x · Cited by 5,347 · cited 2×
“It has been shown by microelectrode recording in brain slices that ethosuximide decreases low-threshold T-type Ca2+ currents in thalamic neurons, and has no effect on the high voltage-activated Ca2+ currents (Coulter et al. 1989; Macdonald and Kelly 1993; White 1999).”
BackgroundEthosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
Flatters, S. J. L., & Bennett, G. J. (2004) · Pain · doi:10.1016/j.pain.2004.01.029 · Cited by 576
Cited by
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036
Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336
Takács, E., Nyilas, R., Szepesi, Z., Baracskay, P., Karlsen, B., Røsvold, T., Bjørkum, A. A., Czurkó, A., Kovács, Z., Kékesi, A. K., et al. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.03.003 · Cited by 63
Inhibition of CaV1.4 channels by CaV3 channel antagonists ML218 and Z944
Sun, J., de la Rosa Vázquez, J., Hernández-González, A., Yarov-Yarovoy, V., & Lee, A. (2026) · Journal of General Physiology · doi:10.1085/jgp.202513879
Metadata
- Authors
- Gören, M. Z., & Onat, F.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2007-06
- Volume
- 13
- Issue
- 2
- Pages
- 224-239
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W1983627046
- Cited by
- 132
- References
- 2
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ethosuximide: From Bench to Bedside. https://app.cochat.ai/papers/10.1111/j.1527-3458.2007.00009.x
- The paper
- Gören, M. Z., & Onat, F. (2007). Ethosuximide: From Bench to Bedside. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2007.00009.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.